Cargando...
Cellular immunotherapy for refractory DLBCL in the CART era: still a role for allogeneic transplantation?
Chimeric antigen receptor-engineered T (CART) cells are a promising new treatment option for patients with multiply relapsed and refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Because of the favourable outcome data reported for CART cells, uncertainty is emerging if there is still a role fo...
Gardado en:
| Publicado en: | Biol Blood Marrow Transplant |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2020
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7207150/ https://ncbi.nlm.nih.gov/pubmed/31917272 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2019.12.771 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|